'Aurobindo Pharma' - 13 Video Result(s)

'Aurobindo Pharma' - 242 News Result(s)

  • Aurobindo Gets US Regulator Nod for Epilepsy, Arthritis Drugs

    Aurobindo Gets US Regulator Nod for Epilepsy, Arthritis Drugs

    Aurobindo Pharma on Tuesday said it has received final approval from the US health regulator for generic versions of Levetiracetam injection used for treating epilepsy as well as anti-arthritis drug Celecoxib.

  • US Regulator Inspects Two Aurobindo Pharma Units

    US Regulator Inspects Two Aurobindo Pharma Units

    Aurobindo Pharma on Monday said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one unit.

  • Aurobindo Pharma Shares Fall on USFDA Concerns

    Aurobindo Pharma Shares Fall on USFDA Concerns

    Shares of Aurobindo Pharma fell as much as 5 per cent to Rs 792.4 on Monday after reports said the pharma companys Unit 3 and Unit 7 of Hyderabad plant were inspected by US health regulator.

  • Aurobindo Pharma Gets USFDA Nod for Fungal Infections Pills

    Aurobindo Pharma Gets USFDA Nod for Fungal Infections Pills

    Aurobindo Pharma has received approval from the US health regulator to manufacture and market generic Voriconazole tablets used for the treatment of fungal infections.

  • Aurobindo Gets US Regulator Nod for Generic Acid Injection

    Aurobindo Gets US Regulator Nod for Generic Acid Injection

    Aurobindo Pharma has received final approval from the USFDA to manufacture and market its Tranexamic acid injection, used for treating hemophilia, in the American market.

  • Aurobindo Pharma Receives US Regulator's Nod for Generic Drug

    Aurobindo Pharma Receives US Regulator's Nod for Generic Drug

    Drug firm Aurobindo Pharma has received approval from the US Food and Drug Administration (FDA) to manufacture and market generic Norethindrone Acetate tablets in the American market.

  • Buy Alkem Labs, India Cements, Aurobindo Pharma: Chandan Taparia

    Buy Alkem Labs, India Cements, Aurobindo Pharma: Chandan Taparia

    Markets are witnessing sustained buying interest since last two trading session. Put-call ratio is moving up and fresh put writing is seen at 7,800 which is indicating that 7,880 is likely to hold for next two trading sessions and Nifty can go up to 7,980-8,000 levels in the next two trading sessions, says Chandan Taparia, derivative analyst with A...

  • Aurobindo Pharma Gets Shareholders' Nod to Raise up to Rs 3,974 Crore

    Aurobindo Pharma Gets Shareholders' Nod to Raise up to Rs 3,974 Crore

    Aurobindo Pharma on Thursday said it has received approval of its shareholders to raise up to $600 million (around Rs 3,974 crore) via securities.

  • Aurobindo Pharma Gets US FDA Nod for Acid Reflux Treatment Drug

    Aurobindo Pharma Gets US FDA Nod for Acid Reflux Treatment Drug

    Aurobindo Pharma Ltd today said it has received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.

  • Aurobindo Pharma Gets US FDA Nod For its Conjunctivitis Drug

    Aurobindo Pharma Gets US FDA Nod For its Conjunctivitis Drug

    Drug firm Aurobindo Pharma has received approval from the US health regulator for generic Olopatadine Hydrochloride ophthalmic solution used for treatment of seasonal allergic conjunctivitis and is ready to launch the product in the American market.

  • US-Based Acorda Therapeutics in Settlement Pact With Aurobindo Pharma

    US-Based Acorda Therapeutics in Settlement Pact With Aurobindo Pharma

    US-based biotechnology company Acorda Therapeutics has said it entered into a settlement agreement with Aurobindo Pharma to resolve a pending patent litigation on Ampyra (dalfampridine) extended-release tablets.

  • Buy Lupin, Fortis Healthcare, Aurobindo Pharma: Shrikant Chouhan

    Buy Lupin, Fortis Healthcare, Aurobindo Pharma: Shrikant Chouhan

    Shrikant Chouhan, technical analyst at Kotak Securities, says that Nifty did not break its previous low of Rs 7,606 on Thursday, which shows that the market has completed its correction based on its time spent at 7,600 levels. One can take long position in Nifty with a stop loss at 7,650, he added.

  • Aurobindo Pharma Gets US Regulator's Nod For Two Drugs, Shares Gain

    Aurobindo Pharma Gets US Regulator's Nod For Two Drugs, Shares Gain

    Aurobindo Pharma shares jumped as much as 2.5 per cent on Thursday, a day after the drugmaker announced that it has received approval for manufacturing and marketing of Eptifibatide Injection and Levonorgestrel Tablets in the US.

  • Aurobindo Pharma Gets US Regulator's Nod for Oral Contraceptive Tablets

    Aurobindo Pharma Gets US Regulator's Nod for Oral Contraceptive Tablets

    Drug firm Aurobindo Pharma has received final approval from the US Food and Drug Administration (FDA) to manufacture and market its oral contraceptive Levonorgestrel tablets.

  • Aurobindo Gets US Regulator's Nod to Market Heart Disease Drug

    Aurobindo Gets US Regulator's Nod to Market Heart Disease Drug

    Aurobindo Pharma has received approval of the US Food and Drug Administration (FDA) to market injection Eptifibatide, used in the treatment of acute coronary syndrome, in the American market.

................................ Advertisement ................................

................................ Advertisement ................................